ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,00%
Bitcoin
67.757,47
0,05%
Brent Oil
81,295
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Graphite Bio Inc (GRPH)

  7. Graphite Bio Inc (GRPH) Notícias

GRPH

Graphite Bio (GRPH)

Graphite Bio Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GRPH
DataHoraFonteTítuloCódigoCompanhia
08/03/202419:17Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:GRPHGraphite Bio Inc
08/03/202419:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GRPHGraphite Bio Inc
08/03/202419:00Business WireGraphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz TherapeuticsNASDAQ:GRPHGraphite Bio Inc
27/02/202418:11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:GRPHGraphite Bio Inc
13/02/202418:44Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GRPHGraphite Bio Inc
09/02/202419:23Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:GRPHGraphite Bio Inc
05/02/202418:31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GRPHGraphite Bio Inc
06/12/202318:57Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:GRPHGraphite Bio Inc
15/11/202309:00Business WireLENZ Therapeutics and Graphite Bio Announce Merger AgreementNASDAQ:GRPHGraphite Bio Inc
13/09/202317:06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:GRPHGraphite Bio Inc
14/08/202318:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GRPHGraphite Bio Inc
21/07/202318:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GRPHGraphite Bio Inc
23/06/202308:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GRPHGraphite Bio Inc
23/06/202308:00Business WireGraphite Bio Announces Departure of Chief Financial OfficerNASDAQ:GRPHGraphite Bio Inc
06/06/202317:16Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:GRPHGraphite Bio Inc
06/06/202317:06Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:GRPHGraphite Bio Inc
11/05/202317:13Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:GRPHGraphite Bio Inc
20/03/202317:18Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:GRPHGraphite Bio Inc
20/03/202317:12Edgar (US Regulatory)Annual Report (10-k)NASDAQ:GRPHGraphite Bio Inc
20/03/202317:05Business WireGraphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial ResultsNASDAQ:GRPHGraphite Bio Inc
22/02/202318:05Business WireGraphite Bio Announces Process to Explore Strategic Alternatives and Corporate RestructuringNASDAQ:GRPHGraphite Bio Inc
05/01/202318:05Business WireGraphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell DiseaseNASDAQ:GRPHGraphite Bio Inc
12/12/202210:42Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:GRPHGraphite Bio Inc
11/12/202212:00Business WireGraphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual MeetingNASDAQ:GRPHGraphite Bio Inc
21/11/202210:00Business WireGraphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx ConferenceNASDAQ:GRPHGraphite Bio Inc
14/11/202201:05TipRanksBTIG Sticks to Their Buy Rating for Graphite Bio (GRPH)NASDAQ:GRPHGraphite Bio Inc
14/11/202200:55TipRanksSVB Securities Sticks to Its Buy Rating for Graphite Bio (GRPH)NASDAQ:GRPHGraphite Bio Inc
10/11/202222:49TipRanksGraphite Bio (GRPH) Receives a Hold from RBC CapitalNASDAQ:GRPHGraphite Bio Inc
09/11/202218:05Business WireGraphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial ResultsNASDAQ:GRPHGraphite Bio Inc
03/11/202210:05Business WireGraphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and ExpositionNASDAQ:GRPHGraphite Bio Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GRPH

Seu Histórico Recente

NYSE
PBR.A
Petroleo Brasileiro ADR
EU
PX1
CAC 40
BOV
ELET3
ELETROBRAS ON
NYSE
PBR
Petroleo Brasileiro ADR
COIN
BTCUSD
Bitcoin
BOV
GFSA3
GAFISA ON
COIN
BRAZBTC
Brazio
BOV
VALE3
VALE ON
BOV
USIM5
USIMINAS PNA
NYSE
RIO
Rio Tinto
BOV
IBOV
Índice Bovespa
COIN
PLUS1BTC
PlusOneCoin
COIN
LTCUSD
Litecoin
COIN
ADABTC
Cardano
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados